Breckenridge Pharmaceutical Inc. June 9 announced that the Food and Drug Administration has approved its generic version of Lamisil (terbinafine hydrochloride tablets), a brand product marketed by Novartis.
Lamisil is indicated for the treatment of toenail or fingernail fungus, according to the drug’s label.
Boca Raton, Fla.-based Breckenridge said it plans to launch the product this summer.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.